Allergy spray could tame COVID symptoms, early trial hopes
NCT ID NCT06008860
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether Astepro, an over-the-counter allergy nasal spray, can help manage early COVID-19 symptoms and reduce viral load. 280 adults with a positive COVID test will use the spray or a placebo for 10 days. Researchers will track symptoms, viral levels, and whether the spray lowers infection rates in close contacts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Astepro (azelastine) nasal spray
- What this could lead to
- If it works, this could offer a simple, over-the-counter nasal spray to reduce COVID-19 symptoms and possibly lower spread to close contacts.
- What could go wrong
- This is a small pilot study, not a large-scale trial. The spray is an antihistamine, not a direct antiviral, so it may not significantly affect the virus or symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?